Exhibit 99.2
©2019 Proteon Therapeutics, Inc. PATENCY - 2 Top - Line Results March 28, 2019
This presentation contains statements that are, or may be deemed to be, "forward - looking statements." In some cases these forwa rd - looking statements can be identified by the use of forward - looking terminology, including the terms “believes,” “estimates,” “anticipates,” "expects,” “plans,” "intends,” “may,” “ could,” “might,” “will,” “should,” “approximately,” “potential,” or, in each case, their negatives or other variations thereon or comparable terminology, although not all forward - looking statements co ntain these words. These statements, including our interpretation of data from PATENCY - 2 and other clinical and pre - clinical studies, the clinical and regulatory path forward for vonapanitase and whether additional studies will be necessary to support a Biologics License Application (BLA), whether and when we may submit a BLA or commercially launch in the United S tat es, our ability to establish a commercially - ready supply chain, our intellectual property position, the significance or clinical utility of any approved product, the market opportuni ty, standard of care and reimbursement for improving fistula outcomes, and those relating to future events or our future financial performance or condition, business strategy, current an d p rospective product candidates, planned clinical trials and preclinical activities, product approvals, research and development costs, current and prospective collaborations, timing and li kelihood of success, plans and objectives of management for future operations, and future results of anticipated product candidates, involve substantial known and unknown risks, uncerta int ies and other important factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forwar d - l ooking statements. These risks, uncertainties and other factors, including whether our cash resources will be sufficient to fund the our operating expenses and capital expenditure r equ irements for the period anticipated; whether data from early clinical trials will be indicative of the data that will be obtained from future clinical trials; whether vonapanitase will a dva nce through the clinical trial process on the anticipated timeline and warrant submission for regulatory approval; whether such a submission would receive approval from the U.S. Food and Drug Admi nis tration or equivalent foreign regulatory agencies on a timely basis or at all; and whether we can successfully commercialize and market our product candidates, are described more f ull y in our Annual Report on Form 10 - K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (“SEC”) on March 13, 2019, and our subsequent Quarter ly Reports on Form 10 - Q and Current Reports on Form 8 - K, as filed with the SEC, particularly in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." In light of the significant uncertainties in our forward - looking statements, you should not place undue reliance on these statements or rega rd these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward - looking st atements contained in this presentation represent our estimates and assumptions only as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise publicly any forward - looking statements, whether as a result of new information, future events or otherwise after the date of this presentation. This presentation also contains estimates, projections and other information concerning our industry, our business, and the m ark ets for our drug candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, proje cti ons, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances re fle cted in this information. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Cautionary Note Regarding Forward - Looking Statements 2
Design Multicenter, randomized, double - blind, placebo - controlled N 603 treated patients in U.S. and Canada Patients Patients with CKD on or expecting to initiate hemodialysis and undergoing surgical creation of a radiocephalic fistula Dose Vonapanitase 30 mcg vs. placebo ( 2:1 randomization) Co - Primary Endpoints Fistula use for hemodialysis Secondary patency (time from fistula surgical creation until fistula abandonment) Other Efficacy Endpoints Primary patency Procedure rate Fistula maturation 3 Phase 3 PATENCY - 2 Trial Design
65.1% 69.7% 0% 10% 20% 30% 40% 50% 60% 70% 80% Placebo Vonapanitase Fistula Use 4 Co - Primary Endpoint: Fistula Use for Hemodialysis Placebo vs. Vonapanitase (p=0.328) • Defined as use of the fistula for two - needle hemodialysis for at least 90 days or, if hemodialysis was not initiated at least 90 days prior to the last study visit, for at least 30 days and including the patient’s last study visit • Results – No statistically significant difference between the arms (p=0.328)
Co - Primary Endpoint: Secondary Patency 5 Defined as time from fistula creation to abandonment Results • No statistically significant difference between the arms (p=0.932) 0 90 180 270 360 450 0 20 40 60 80 100 Secondary Patency Days P e r c e n t s u r v i v a l Placebo Vonapanitase
Other Endpoint: Primary Unassisted Patency 6 Defined as time from fistula creation to first occurrence of a fistula thrombosis or corrective procedure to restore or maintain patency Results • No statistically significant difference between the arms (p=0.178) 0 90 180 270 360 450 0 20 40 60 80 100 Primary Unassisted Patency Days P e r c e n t s u r v i v a l Placebo Vonapanitase
• No evidence of immunogenicity • Adverse events consistent with medical conditions experienced by kidney disease patients undergoing fistula surgery • Adverse events comparable for vonapanitase and placebo 7 PATENCY - 2 Safety Profile Includes any adverse event that occurred in at least 5% of patients in either treatment group. Adverse Events Vonapanitase (n=399) Placebo (n=204) Vascular stenosis 35.1% 41.7% Fistula thrombosis 16.8% 18.6% Local swelling 5.0% 2 .0 % Hematoma 5.0% 3.9%
©2019 Proteon Therapeutics, Inc. PATENCY - 2 Top - Line Results March 28, 2019